The abstract is read at the publisher; the summary is JClub's.
Metformin-isothiocyanate (Met-ITC) preserves metformin’s antidiabetic activity and adds H2S-derived vascular protection in db/db mice, improving glucose tolerance and endothelial/smooth muscle resilience.
- Why it matters: People with type 2 diabetes on metformin still face high cardiovascular risk, and H2S-releasing hybrids may better address diabetes-linked vascular dysfunction than metformin alone.
- What they did: The study used in silico ADME comparisons, then tested glucose uptake in HepG2 cells and oral glucose tolerance in db/db mice; it also assessed H2S release, ROS, viability, and senescence in HAECs/HASMCs under oxidative, homocysteine, or high-glucose stress.
- The result: Met-ITC had a more favorable permeability profile than metformin, protected cells more effectively against oxidative stress, loss of viability, and senescence, and in rat aortic rings caused concentration-dependent HASMC hyperpolarization, reduced noradrenaline contraction, and induced vasodilatation.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.